Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24720256 | 0.88 | SOS1 (0.39) | SOS1SOS2 | |
| SCHEMBL27443832 | 0.86 | SOS1 (0.52) | SOS1SOS2 | |
| SCHEMBL21945578 | 0.85 | SOS1 (0.46) | SOS1SOS2 | |
| SCHEMBL25124976 | 0.85 | SOS1 (0.46) | SOS1SOS2 | |
| SCHEMBL21210664 | 0.83 | SOS1 (0.48) | SOS1SOS2 | |
| SCHEMBL17789639 | 0.82 | SOS1 (0.45) | SOS1SOS2 | |
| SCHEMBL22989400 | 0.81 | SOS1 (0.34) | SOS1SOS2 | |
| SCHEMBL24568091 | 0.78 | SOS1 (0.41) | SOS1SOS2 | |
| SCHEMBL25959539 | 0.77 | — | — | |
| SCHEMBL20202089 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20210130369-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | SOS1 566/4885SOS2 744/4885 |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, RBM17, SNRPB2 | SOS1 2838/4885SOS2 2735/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | SOS1 55/4885SOS2 88/4885 |
| US-20210130369-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | SOS1 55/4885SOS2 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.